1. Gastro-resistant compacted pharmaceutical composition containing one or more enzymes self-organized in such a way that the enzymes have a greater adhesion after compaction than before compaction, where the enzymes in the pharmaceutical composition retain at least 30% of their activity after exposure to the pharmaceutical composition simulating gastric juice for 1 hour at 37 ° C. 2. The composition according to claim 1, wherein the composition turns into a self-coated in situ upon contact with gastric juices, restricting further fluid penetration. The composition of claim 1, wherein the composition contains one or more enzymes selected from amylases, lipases, and proteases. The composition of claim 1, wherein the composition has a drug content of at least 65% by weight. The composition of claim 1, wherein the composition is not enteric coated. The composition of claim 1, wherein the composition is monolithic. A composition according to claim 1, wherein the composition is mixed together with enteric-coated pancreatlipase compositions. The composition according to claim 1, where the composition was pressed with a pressing force of from about 0.25 to about 3.0 T. 9. A monolithic compacted gastro-resistant pharmaceutical composition containing pancrelipase, wherein pancrelipase contains a mixture of lipase, amylase and protease, where the lipase and amylase in the tablet retain at least 80% and 30% of their activity, respectively, after exposure to simulated gastric juice for 2 hours and the protease in the tablet retains at least 70% of its activity after exposure to simulated gastric juice for 0.5 hours. The composition according to claim 9, where the composition can be obtained posr1. Желудочно-резистентная уплотненная фармацевтическая композиция, содержащая один или несколько ферментов, самоорганизованных таким образом, что ферменты имеют большую силу сцепления после уплотнения, чем до уплотнения, где ферменты в фармацевтической композиции сохраняют по меньшей мер
